Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Report from the ESMO 2017 Congress, Madrid, 8th–12th September, 2017

Report from the ESMO 2017 Congress, Madrid, 8th–12th September, 2017 special issue ESMO 2017 ESMO 2017 Table of Contents S72 Preface S72 Immunotherapy: once more at the cutting edge of progress S77 Immunostimulation as a promising approach in SCLC S78 Randomised findings on CT-based follow-up after resection of early NSCLC S79 EGFR-mutant lung cancer: sequencing as a major topic in light of new data S81 Interview: Survival is the result of multiple treatment lines S82 Reaching unprecedented outcome S85 ALK-positive NSCLC: updates on crizotinib dimensions in malignant mesothelioma and alectinib S84 Characteristics and outcomes for SCLC S87 Rare driver mutations: BRAF- and arising from transformation HER2-mutant NSCLC Editorial Board: Alex A. Adjei, MD, PhD, FACP, Roswell Park, Cancer Institute, New York, USA Maria Rosario Garcia Campelo, MD, Lung Cancer and Thoracic Tumors, University Hospital Quirón A Coruña, La Coruña, Spain Federico Cappuzzo, MD, Medical Oncology Department, Ospedale Civile di Livorno, Livorno, Italy Wolfgang Hilbe, MD, Departement of Oncology, Hematology and Palliative Care, Wilhelminenspital, Vienna, Austria Maximilian Hochmair, MD, 1. Interne Lungenabteilung, Otto-Wagner-Spital, Vienna, Austria Massimo Di Maio, MD, National Institute of Tumor Research and Therapy, Foundation G. Pascale, Napoli, Italy Filippo de Marinis, MD, PhD, Director of the Thoracic Oncology Division at the European Institute of Oncology (IEO), Milan, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Report from the ESMO 2017 Congress, Madrid, 8th–12th September, 2017

memo - Magazine of European Medical Oncology , Volume 10 (4) – Oct 30, 2017

Loading next page...
 
/lp/springer-journals/report-from-the-esmo-2017-congress-madrid-8th-12th-september-2017-iopTRkXAKK
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer-Verlag GmbH Austria
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-017-0360-2
Publisher site
See Article on Publisher Site

Abstract

special issue ESMO 2017 ESMO 2017 Table of Contents S72 Preface S72 Immunotherapy: once more at the cutting edge of progress S77 Immunostimulation as a promising approach in SCLC S78 Randomised findings on CT-based follow-up after resection of early NSCLC S79 EGFR-mutant lung cancer: sequencing as a major topic in light of new data S81 Interview: Survival is the result of multiple treatment lines S82 Reaching unprecedented outcome S85 ALK-positive NSCLC: updates on crizotinib dimensions in malignant mesothelioma and alectinib S84 Characteristics and outcomes for SCLC S87 Rare driver mutations: BRAF- and arising from transformation HER2-mutant NSCLC Editorial Board: Alex A. Adjei, MD, PhD, FACP, Roswell Park, Cancer Institute, New York, USA Maria Rosario Garcia Campelo, MD, Lung Cancer and Thoracic Tumors, University Hospital Quirón A Coruña, La Coruña, Spain Federico Cappuzzo, MD, Medical Oncology Department, Ospedale Civile di Livorno, Livorno, Italy Wolfgang Hilbe, MD, Departement of Oncology, Hematology and Palliative Care, Wilhelminenspital, Vienna, Austria Maximilian Hochmair, MD, 1. Interne Lungenabteilung, Otto-Wagner-Spital, Vienna, Austria Massimo Di Maio, MD, National Institute of Tumor Research and Therapy, Foundation G. Pascale, Napoli, Italy Filippo de Marinis, MD, PhD, Director of the Thoracic Oncology Division at the European Institute of Oncology (IEO), Milan,

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Oct 30, 2017

There are no references for this article.